Skip to main content
RaySearch Laboratories logo

RaySearch Laboratories — Investor Relations & Filings

Ticker · RAY ISIN · SE0000135485 LEI · 549300TYFVYGS0JFWM28 ST Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 590 across all filing types
Latest filing 2008-08-27 Interim / Quarterly Rep…
Country SE Sweden
Listing ST RAY

About RaySearch Laboratories

https://www.raysearchlabs.com/

RaySearch Laboratories develops advanced software solutions for radiation therapy and oncology. The company's product suite includes the RayStation® treatment planning system, the RayCare® oncology information system, and the RayIntelligence® oncology analytics system. These integrated platforms are engineered to enhance the efficiency, precision, and automation of cancer treatment workflows for clinics worldwide. By collaborating with leading cancer centers and research institutions, RaySearch aims to accelerate innovation in the field. The software is used by thousands of clinics to help clinicians plan and manage complex treatments, ultimately working to improve patient outcomes in the fight against cancer.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2008
Interim / Quarterly Report Classification · 100% confidence The document is explicitly titled 'Interim Report January 1 – June 30, 2008'. It contains comprehensive financial statements, including income statements, balance sheet data, and detailed management commentary on business performance, market trends, and future outlook for the specified six-month period. It is not a mere announcement or certification, but the full interim financial report itself. H1 2008
2008-08-27 English
Regulatory Filings 2008
Regulatory Filings Classification · 90% confidence The document is a press release dated August 13, 2008, announcing a research collaboration between RaySearch Laboratories AB and Massachusetts General Hospital (MGH) regarding multi-objective optimization for radiation therapy. This announcement details a strategic partnership and development goal, which does not fit neatly into standard financial reporting categories like 10-K, ER, or IR. It is not a management change (MANG), director dealing (DIRS), dividend notice (DIV), or a formal regulatory filing like a proxy statement (PSI) or major shareholding notice (MRQ). Since it is a specific, non-financial corporate announcement concerning strategic development and partnership, and it doesn't fit the other specific categories (like M&A (TAR) or Capital Change (CAP)), the most appropriate general category for a specific corporate announcement that isn't a standard financial report or governance document is the fallback category, Regulatory Filings (RNS), as it is a formal public announcement. However, upon reviewing the definitions, this is a specific corporate development announcement. It is not a financial report, a management change, or a shareholder vote result. Given the options, RNS (Regulatory Filings) serves as the best catch-all for specific, non-standard corporate news releases that are not covered elsewhere. It is a formal public announcement, often disseminated via regulatory channels.
2008-08-13 Swedish
Regulatory Filings 2008
Regulatory Filings Classification · 94% confidence The document is a press release dated August 13, 2008, announcing a research collaboration agreement between RaySearch Laboratories AB and Massachusetts General Hospital (MGH) regarding radiation therapy software development. This announcement details a strategic partnership and R&D focus, which does not fit the definitions for standard financial reports (10-K, IR, ER), shareholder actions (DIV, DVA), or management changes (MANG). It is a specific announcement regarding a business development or strategic alliance. Since there is no specific category for 'Research Collaboration Announcement' or 'Strategic Partnership,' and it is not a general regulatory filing (RNS) or a presentation (IP), the most appropriate classification based on the provided definitions is to treat it as a general business update that doesn't fit the highly specific financial or corporate governance categories. However, given the context of financial reporting databases, announcements of significant business developments that aren't explicitly covered (like M&A or Financing) often fall under a general regulatory or miscellaneous announcement category. Since it is a formal press release announcing a significant business development, and it doesn't fit any other category perfectly, RNS (Regulatory Filings - general fallback) is the best fit among the options, although 'LTR' (Legal Proceedings Report) or 'TAR' (M&A Activity) are clearly incorrect. Given the nature of the announcement (a business development/partnership), and lacking a better fit, RNS serves as the catch-all for non-standard announcements.
2008-08-13 English
Regulatory Filings 2008
Regulatory Filings Classification · 95% confidence The document is a press release dated August 5, 2008, announcing a consulting agreement between RaySearch Laboratories AB and Uppsala University Hospital for the development of a proton therapy system. It details a strategic partnership and development area, but it does not contain comprehensive financial statements (like 10-K or IR), specific voting results (DVA), management changes (MANG), or a formal earnings announcement (ER). Since it announces a specific business development, partnership, and strategic importance without fitting neatly into the other specific categories (like M&A, Financing, or Director Dealing), it best fits the general 'Regulatory Filings' fallback category, which often captures significant, non-standard corporate news releases that aren't covered by other specific codes like DIV or CAP. Given the short length and nature as a news announcement, RNS is the most appropriate general regulatory filing category.
2008-08-05 English
Regulatory Filings 2008
Regulatory Filings Classification · 91% confidence The document is a press release dated August 5, 2008, announcing a consulting agreement between RaySearch Laboratories AB and Akademiska sjukhuset regarding the development of a proton therapy dosimetry planning system. This announcement details a strategic partnership and development milestone, but it does not fit neatly into the specific financial reporting categories like 10-K, ER, or IR. It is not a formal regulatory filing (like a DIRS or MRQ), nor is it a presentation (IP) or a transcript (CT). Since it is a specific, non-standard announcement concerning business development and strategic partnerships that doesn't align with the other defined categories (like M&A, Financing, or Management changes), the most appropriate fallback category is Regulatory Filings (RNS), which serves as a general category for miscellaneous regulatory announcements.
2008-08-05 Swedish
Regulatory Filings 2008
Regulatory Filings Classification · 92% confidence The document is a press release dated June 25, 2008, announcing a license agreement extension between RaySearch and Philips for a VMAT treatment planning product (SmartArc). This announcement details a business development, partnership, and product integration, which does not fit the specific definitions for financial reports (10-K, IR, ER), governance documents (DEF 14A, CGR), or shareholder actions (DIV, DVA). It is a general business update regarding a strategic partnership and technology licensing. Among the provided codes, 'Regulatory Filings' (RNS) is the most appropriate fallback for a general press release about a commercial agreement that doesn't fit a more specific category like M&A (TAR) or Capital Change (CAP). Given the nature of the announcement (a commercial agreement extension), RNS serves as the best general regulatory/news announcement category.
2008-06-25 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.